Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

Our Top 5 Analyst Questions Eli Lilly’s Q1 Earnings Call Asad Haider (Goldman Sachs) asked about the impact of the CVS formulary loss on Zepbound’s market share and future PBM dynamics.

Friday, June 13, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today’s Research Daily features new research reports on 16 major stocks, including Eli Lilly ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to pricing and access to its drug Zepbound emerged. The company's GLP-1 ...

Eli Lilly cut its outlook for fourth-quarter revenue as the market for drugs that increase insulin levels grew slower than expected, but the company sees healthy growth in 2025 due to the success ...

Eli Lilly's business is growing fast, but it wasn't enough for analysts and investors. It also slashed its earnings guidance for the year. The stock has been trading at a high valuation, and that ...

28 analysts have shared their evaluations of Eli Lilly (NYSE:LLY) during the recent three months, expressing a mix of bullish and bearish perspectives.Summarizing their recent assessments, the ...

Eli Lilly (NYSE:LLY) shares rose ~10% in premarket trading on Thursday after the company, with its Q2 2024 financials, increased its full-year outlook above consensus as its weight loss products ...

Across the recent three months, 25 analysts have shared their insights on Eli Lilly and Co (NYSE:LLY), expressing a variety of opinions spanning from bullish to bearish.The following table ...

Chris Shibutani, an analyst from Goldman Sachs, maintained the Hold rating on Eli Lilly & Co (LLY – Research Report). The associated price target is $650.00. Geoff Meacham has given his Hold ...

On average, analysts polled by Thomson Reuters expect the company to report earnings of $8.71 per share on revenues of $31.44 billion for the year. Analysts' estimates typically exclude special items.